There is evidence that H3 receptors
have a role in learning and memory processes.
Gliatech has developed selective agents, which can block or stimulate histamine's actions at the H3 receptor
Gliatech has developed selective antagonists to the histamine H3 receptor
Perceptin(TM) is the Company's selective histamine H3 receptor
antagonist which is being developed for potential use in central nervous system diseases involving attention/learning or sleep disorders.
Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor
antagonist, both for the treatment of obese individuals, and for attenuating drug associated side effects, such as weight gain associated antipsychotic drugs' histamine inhibition.
These include patents covering the histamine H3 receptor
, a hypothalamic G-protein-coupled receptor (GPCR) important in appetite control (U.
Obecure is investigating the drug, an H1 receptor agonist and partial H3 receptor
antagonist, for the treatment of obese individuals and for other weight management indications.
The histamine H3 receptor
is predominantly found in the brain where it regulates the release of histamine.
This portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor
antagonists, PPARd agonists, and 11bHSD1 inhibitors.
The profile for this selective histamine H3 receptor
antagonist is unique.